3 US Penny Stocks With Market Caps Over $40M To Consider

In This Article:

As the U.S. stock market takes a breather following a post-election rally, investors are keenly observing opportunities that might arise in different sectors. Penny stocks, despite their somewhat outdated name, remain relevant as they often represent smaller or newer companies with potential for growth. With strong financial foundations and solid fundamentals, these stocks can offer valuable opportunities for those willing to explore beyond the well-trodden paths of larger firms.

Top 10 Penny Stocks In The United States

Name

Share Price

Market Cap

Financial Health Rating

BAB (OTCPK:BABB)

$0.839

$5.67M

★★★★★★

RLX Technology (NYSE:RLX)

$1.59

$2.03B

★★★★★★

QuantaSing Group (NasdaqGM:QSG)

$3.08

$161.01M

★★★★★★

AsiaFIN Holdings (OTCPK:ASFH)

$1.00

$79.11M

★★★★★★

Data Storage (NasdaqCM:DTST)

$4.94

$33.86M

★★★★★★

PHX Minerals (NYSE:PHX)

$3.34

$125.56M

★★★★★☆

So-Young International (NasdaqGM:SY)

$1.25

$86.82M

★★★★☆☆

Golden Growers Cooperative (OTCPK:GGRO.U)

$4.50

$69.71M

★★★★★★

Better Choice (NYSEAM:BTTR)

$2.096

$3.92M

★★★★★★

CBAK Energy Technology (NasdaqCM:CBAT)

$0.975

$91.29M

★★★★★☆

Click here to see the full list of 739 stocks from our US Penny Stocks screener.

Here's a peek at a few of the choices from the screener.

Ikena Oncology

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Ikena Oncology, Inc. is a U.S.-based oncology company focused on developing differentiated therapies targeting cancer growth, spread, and resistance, with a market cap of approximately $84.45 million.

Operations: No revenue segments have been reported.

Market Cap: $84.45M

Ikena Oncology, Inc., with a market cap of US$84.45 million, is currently pre-revenue and unprofitable, reporting less than US$1 million in revenue. Despite this, the company has no debt and a robust cash position with short-term assets of US$141.5 million exceeding liabilities significantly. It has enough cash runway for 2.5 years if current cash burn trends continue. Recent earnings reports show reduced losses compared to the previous year, although profitability isn't expected soon. The management team is relatively new with an average tenure of 1.1 years, while board members have more experience at four years on average.

NasdaqGM:IKNA Financial Position Analysis as at Nov 2024
NasdaqGM:IKNA Financial Position Analysis as at Nov 2024

MediciNova

Simply Wall St Financial Health Rating: ★★★★★★

Overview: MediciNova, Inc. is a biopharmaceutical company that develops novel small molecule therapeutics for serious diseases with unmet medical needs in the United States and has a market cap of $75.04 million.

Waiting for permission
Allow microphone access to enable voice search

Try again.